Last Updated: November 8, 2026

Details for Patent: 12,576,067

Name: Drug Patent Intelligence for US Patent 12576067
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which drugs does patent 12,576,067 protect, and when does it expire?

Patent 12,576,067 protects RYZUMVI and is included in one NDA.

This patent has thirty patent family members in twenty-three countries.

Summary for Patent: 12,576,067

Title:	Methods and compositions for treatment of mydriasis
Abstract:	The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
Inventor(s):	Mina Sooch, Alan R. Meyer, Konstantinos Charizanis, Bernhard Hoffmann, William H. Pitlick
Assignee:	Opus Genetics Inc
Application Number:	US19/029,592
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,576,067
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form;

Drugs Protected by US Patent 12,576,067

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes	12,576,067	⤷ Start Trial				TREATMENT OF PHARMACOLOGICALLY-INDUCED MYDRIASIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 12,576,067

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019366451	⤷ Start Trial
Australia	2024219970	⤷ Start Trial
Brazil	112021007725	⤷ Start Trial
Canada	3116589	⤷ Start Trial
China	113164452	⤷ Start Trial
Denmark	3870170	⤷ Start Trial
European Patent Office	3870170	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.